Tonix Pharmaceuticals Holding Corp. (TNXP) is a biopharmaceutical company based in Chatham, New Jersey, focused on developing innovative therapies for central nervous system disorders and rare diseases. The company is advancing a diversified pipeline of proprietary drug candidates, particularly targeting unmet medical needs in mental health and pain management. With a robust expertise in drug formulation and delivery, Tonix is strategically positioned to capitalize on opportunities in the healthcare market, potentially establishing itself as a leader in the pharmaceutical sector as it navigates its clinical programs toward commercialization. Show more

Location: 26 MAIN STREET, CHATHAM, NJ, UNITED STATES, 07928, Chatham, NJ, 07928, USA | Website: https://www.tonixpharma.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE


Market Cap

190.2M

52 Wk Range

$6.76 - $69.97

Previous Close

$17.24

Open

$17.20

Volume

269,465

Day Range

$16.95 - $18.19

Enterprise Value

13.4M

Cash

190.1M

Avg Qtr Burn

-28.78M

Insider Ownership

0.03%

Institutional Own.

24.91%

Qtr Updated

09/30/25


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

TNX-4800 Details
Lyme Disease

Phase 2/3

Initiation

TNX-1900 Details
Psychiatric disorder, Binge eating disorder

Phase 2

Data readout

TNX-1300 Details
Cocaine overdose / intoxication

Phase 2

Data readout

TNX-1900 Details
Bone disorder, Bone health, Autism spectrum disorders

Phase 2

Data readout

Phase 2

Data readout

TNX-1900 Details
Social Anxiety Disorder

Phase 2

Data readout

TNX-102 SL Details
Acute Stress Reaction

Phase 2

Data readout

Phase 2

Update

TNX-102 SL Details
Sleeping disorder, Post-traumatic stress disorder

Phase 2

Update

TNX-2900 Details
Prader-Willi syndrome

Phase 2

Initiation

TNX-102 SL Details
Major Depressive Disorder

Phase 2

Initiation

TNX-1500 Details
Kidney transplantation, Graft-versus-host disease , Hematopoietic cell transplantation

Phase 2

Initiation

IND

Submission

TNX-102 SL Details
Agitation, Alzheimer's disease

Failed

Discontinued

TNX-102 SL Details
Alcohol dependence

Failed

Discontinued

Failed

Discontinued

TNX-601 Details
Major depressive disorder

Failed

Discontinued